Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement

Knee Osteoarthritis Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00911469
• Other study ID #: 27575
• Status: Completed
• Phase: Phase 1
• First received: May 29, 2009
• Last updated: August 4, 2014
• Start date: November 2007
• Est. completion date: June 2010

Study information

• Verified date: August 2014
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencySweden: Medical Products AgencyDenmark: Danish Dataprotection AgencyFinland: Finnish Medicines AgencyBulgaria: Bulgarian Drug AgencySouth Africa: Medicines Control Council
• Study type: Interventional

Clinical Trial Summary

Osteoarthritis (OA) is one of the most common diseases affecting the joints, usually those that are weight bearing such as the knees. OA is considered to be a disease of the cartilage in the joints even though it involves the whole joint, including the bone and synovium (thin lining of the joints which produces synovial fluid). With time, more and more of the cartilage is destroyed by the disease with inflammation commonly occurring.

AS902330 is expected to increase the production and development of specific bone cells:

chondrocytes and osteoblasts (cells that produce and maintain bone and cartilage). This is expected to lead to repair and regeneration of the cartilage, and a narrowing of the space width between the knee joints in a selected region of the knee.The purpose of this study is to see how safe treatment with AS902330 is, and to evaluate its effect on the knee cartilage. In addition, the study will also measure the effects of AS902330 in the blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: June 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Established diagnosis of knee primary femoro-tibial OA by standard American College of Rheumatology Criteria (ACR) for at least six months (clinical AND radiological criteria)

2. Postmenopausal or surgically sterile female = 40 years of age Post-menopausal status will be confirmed by no menstrual periods for 12 consecutive months and no other biological or physiological cause for amenorrhea can be identified or Male = 40 years of age willing to use contraception (condom with spermicide) from the first day of treatment until 2 months after the end of the treatment (3rd injection in Period 2) Even though systemic exposure of the drug is not foreseen at the doses used in this study, due to the absence of data on teratogenic potential of the drug, a very conservative approach on contraception is taken based on the spermatogenesis duration in humans.

3. Candidate for Total Knee Replacement in the target knee, according to NIH consensus statement on Total Knee Replacement (2003)

4. Date of planned Total Knee Replacement in the target knee = 2 weeks after the anticipated last injection of study drug

5. Subjects may be on treatment for symptomatic relief of OA, including NSAIDs (including Cox2 specific inhibitors); for NSAIDs, the dose should be stable for 4 weeks before baseline and during the study until day 4 after last injection. Paracetamol/acetaminophen (according to local standards and up to 4 grams per day) is allowed as rescue medication

6. Willingness to stay in hospital for 24h after injection for SAD regimens and after first injection for MAD regimens (and up to 4 hours after second and third injections for MAD regimens) for safety and PK evaluation

7. Willingness to complete a diary card to evaluate local tolerability and adverse events throughout the study

8. Subjects must have read and understood the informed consent form and must have signed it prior to any study related procedure

9. Subjects must fully understand the requirements of the study and be willing to comply with all study visits and assessments

Exclusion Criteria:

1. Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation

2. Clinically significant abnormal hematology or biochemistry values (platelets, hemoglobin, leucocytes, alkaline phosphatase, AST, ALT, blood creatinine, bilirubin)

3. Receipt of any investigational product or any experimental therapeutic procedure within the last 12 weeks preceding screening

4. Intra-articular treatment with steroids or hyaluronic acid derivatives within the past 3 months (systemic symptomatic treatments with NSAIDs are allowed when stable for 4 weeks prior to first injection)

5. Planned major surgery (e.g. joint replacement) within 2 weeks after last injection

6. History of previous surgery (TKR or partial knee replacement) on the target knee

7. Lesions at the planned injection site that would present a contra-indication to local injection of the study drug (e.g., open wounds and infections of the skin)Any drug or nutraceutical treatment with potential DMOAD effect (glucosamine, diacerin, chondroitin sulfate) unless given at a stable dose over at least 4 weeks prior to first injection

8. Use of electrotherapy or acupuncture for OA

9. Any known active infections, including suspicion of intra-articular infection and/or infections that may compromise the immune system such as HIV, Hepatitis B or Hepatitis C infection

10. History of sarcoma and/or history of other active malignancy within five years, except adequately treated basal cell and squamous cell carcinoma of the skin

11. Signs and symptoms suggestive of transmissible spongiform encephalopathy

12. Secondary osteoarthritis: e.g. Joint dysplasias, Aseptic osteonecrosis, Acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, Joint infection, Hemophilia, Hemochromatosis, Calcium Pyrophosphate deposition disease, or Neuropathic arthropathy whatever the cause Patients with risk factors for knee OA (e.g. obesity, meniscectomy) are not considered as having secondary OA and can be included in this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• AS902330
3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
• Placebo
Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.

Locations

Country	Name	City	State
Bulgaria	UMHAT "Sv. Ivan Rilski", Clinical Research Unit for Phase I	Sofia
Denmark	Frederiksberg Hospital	Frederiksberg
Denmark	Gentofte Hospital	Hellerup
Denmark	Nordsjællands Hospital - Hørsholm	Hørsholm
Denmark	Silkeborg sygehus	Silkeborg
Denmark	Regionshospitalet Viborg	Viborg
Finland	Kuopio University Hospital	Kuopio
Finland	Oulu University Hospital	Oulu
Finland	Turku University Central Hospital	Turku
South Africa	FARMOVS-PAREXEL (Pty) Ltd, University of the Free State	Bloemfontein
South Africa	PAREXEL-George	George
South Africa	PAREXEL-Port Elizabeth, Mercantile Hospital	Port Elizabeth
Sweden	Sahlgrenska University Hospital/Östra	Göteborg
Sweden	Hässleholms Sjukhus	Hässleholm
Sweden	Kungälv Sjukhus	Kungälv
Sweden	Lund University Hospital	Lund
Sweden	Malmö University Hospital	Malmö
Sweden	Danderyds Sjukhus	Stockholm
United Kingdom	Cambridge University Hospitals	Cambridge

Sponsors (2)

Lead Sponsor	Collaborator
Merck KGaA	Merck Serono S.A., Geneva

Countries where clinical trial is conducted

Bulgaria,  Denmark,  Finland,  South Africa,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nature, incidence and severity of treatment-emergent adverse events (TEAEs)		Up to 24 weeks post treatment	Yes
Primary	Proportion of subjects with predefined local AEs (acute inflammatory reactions defined as increase of pain by 30 mm - on a 100 mm VAS - associated with a self-reported synovial fluid effusion within 3 days following i.a. injection)		Up to 24 weeks post treatment	Yes
Primary	Local tolerability in the target knee		Up to 24 weeks post treatment	Yes
Primary	Laboratory safety parameters (including blood chemistry, haematology, and urinalysis) and ECG		Up to 24 weeks post treatment	Yes
Secondary	Change over time in the levels of the following biomarkers: Biomarkers of anabolic effect on knee cartilage (markers of cartilage formation/synthesis)		Up to 24 weeks post treatment	Yes
Secondary	Change over time in the levels of the following biomarkers: Biomarkers of catabolic effect on knee cartilage (markers of cartilage degradation)		Up to 24 weeks post treatment	Yes
Secondary	Change over time in the levels of the following biomarkers: Biomarkers of Bone Metabolism		Up to 24 weeks post treatment	Yes
Secondary	Change in levels of cytokines related to inflammation (IL1b, IL6, IL8, TNFa and IFNa)		Up to 24 weeks post treatment	Yes
Secondary	Blood levels of AS902330		Up to 24 weeks post treatment	Yes
Secondary	Presence of anti-AS902330 antibodies		Up to 24 weeks post treatment	Yes